Skip to main content
Oncology RegulationSummit Therapeutics· 6 min read· in Health

FDA Rejects Summit Therapeutics' Lung Cancer Drug Ivonescimab Over Survival Data

The US Food and Drug Administration has declined to approve the bispecific antibody ivonescimab for first-line lung cancer treatment. The decision delays the US arrival of a highly anticipated drug class after the underlying clinical trial missed a key overall survival goal.

By Sofia Delgado

Share this story

Listen

Lung cancer treatment relies heavily on continuous innovation, and a new class of dual-targeting drugs recently promised a 34 percent improvement in progression-free survival overseas. For the hundreds of thousands of patients monitoring the pipeline, that timeline halted today. The regulatory hurdle proved too high for the initial data package.[2]

The US Food and Drug Administration rejected the biologics license application for ivonescimab. The medication, developed jointly by US-based Summit Therapeutics and China-based Akeso, targeted a narrow first-line setting for non-small cell lung cancer. The agency formalized the rejection through a complete response letter.[1][2][6]

According to Endpoints News, this regulatory block effectively derails the immediate US arrival of the highly anticipated PD-1xVEGF drug class. The decision forces developers to reevaluate their clinical trial strategies. It also leaves current standard-of-care regimens unchallenged in the immediate term.[2]

The rejection centers on specific clinical trial endpoints. Reuters reports that the FDA declined to approve the medication after the underlying study missed a key survival goal. In oncology, the distinction between delaying tumor growth and extending total lifespan dictates regulatory success.[4]

Initial reports and corporate press releases from Summit Therapeutics did not include direct quotations from FDA officials or company executives regarding the specific clinical deficiencies. The company acknowledged the update regarding its application without detailing the exact statistical shortfalls.[6]

Dual-Targeting Biological Mechanism

To understand the 2026 setback, patients must look at how ivonescimab operates at the cellular level. The drug is a bispecific antibody, meaning researchers engineered it to bind to two distinct cellular targets simultaneously. Traditional monoclonal antibodies typically block only one pathway.[1][3]

Bispecific antibodies like ivonescimab are engineered to bind to two distinct cellular targets simultaneously.

The first target is PD-1, a checkpoint protein found on immune cells. Tumors frequently exploit the PD-1 pathway to hide from the body's natural defenses. Blocking this checkpoint strips away the tumor's disguise, allowing T-cells to recognize and attack the malignant tissue.[3]

The second target is VEGF, a protein that stimulates the formation of new blood vessels. Tumors require a robust, continuous blood supply to grow and spread throughout the body. Inhibiting VEGF starves the cancer of the oxygen and nutrients it needs to expand.[3]

By combining these two blockades into a single molecule, researchers hoped to starve the tumor while simultaneously triggering an immune response. Early overseas data suggested this dual approach outperformed single-target therapies. The biological rationale remains sound, even as the regulatory execution falters.[1][2]

BioSpace notes that the rejection specifically impacts the drug's application in lung cancer. Non-small cell lung cancer accounts for roughly 85 percent of all lung cancer diagnoses globally. This massive patient population makes the disease a primary focus for pharmaceutical development and regulatory scrutiny.[3]

Survival Goals and Trial Demographics

The core of the FDA's decision rests on the critical distinction between different types of survival data. In phase 3 oncology trials, researchers typically measure both progression-free survival and overall survival. These two metrics tell different stories about a drug's efficacy.[4]

Progression-free survival tracks how many months a patient lives without their disease worsening on scans. Ivonescimab previously demonstrated strong results in this category during its HARMONi-2 trial in China. However, delaying tumor growth does not always translate to a longer life.[2][5]

Overall survival measures the total duration patients remain alive after starting the treatment. Reuters indicates that the ivonescimab trial missed this specific, rigorous survival goal. Regulatory agencies view overall survival as the definitive gold standard for approving new cancer therapies.[4]

A drug that shrinks a tumor but fails to extend a patient's total lifespan struggles to secure authorization in the United States. The FDA prioritizes treatments that offer a proven, measurable extension of life over those that only offer temporary stabilization.[4]

While progression-free survival tracks delayed tumor growth, the FDA increasingly demands proof of extended overall survival.

Furthermore, the geographic origin of the clinical data plays a significant role in FDA evaluations. NDTV Profit highlights that ivonescimab is a China-originated drug, relying heavily on overseas clinical trial populations. This reliance introduces demographic variables that complicate US regulatory reviews.[5]

The FDA maintains strict standards regarding the demographic diversity of clinical trials. The agency requires that study populations reflect the genetic and ethnic makeup of the US patients who will ultimately receive the medication. Data generated exclusively in one country rarely meets this standard.[2][5]

Industry Ripples and Next Steps

Summit Therapeutics now faces a complex regulatory pathway to salvage the drug's US prospects. The company must address the specific deficiencies outlined in the FDA's complete response letter. This process often takes months of negotiation and data reanalysis.[1][6]

Fierce Pharma reports that this rejection derails the broader US arrival of the PD-1xVEGF class. Several other pharmaceutical companies are currently developing similar bispecific antibodies. This FDA decision sets a strict regulatory precedent that competing drugmakers must now navigate.[1]

To secure future approval, Summit and Akeso will likely need to generate additional clinical data. This typically involves launching new, multi-regional phase 3 trials that include significant cohorts of US-based patients. These trials must be designed from the ground up to capture overall survival.[2][6]

These required studies must demonstrate a clear survival benefit against the current standard of care. In the first-line lung cancer setting, that standard is usually pembrolizumab. Beating a deeply entrenched and highly successful immunotherapy requires overwhelming statistical evidence.[2]

Running a new global oncology trial requires immense financial resources and years of patient follow-up. Industry analysts expect that any potential US launch for ivonescimab is now delayed until at least the late 2020s. The timeline for innovation is inherently slow.[1][2]

Despite the regulatory setback, the underlying science of bispecific antibodies remains a focal point for researchers. The dual-targeting approach still holds theoretical promise. The challenge lies entirely in executing clinical trials that meet the FDA's stringent, uncompromising survival metrics.[1][3]

Illustration: Pharmaceutical developers must now reevaluate their clinical trial strategies to meet strict US regulatory standards.

Practical Guidance for Patients

For individuals navigating a recent lung cancer diagnosis, this regulatory news requires no immediate change in strategy. The US market already features multiple highly effective, FDA-approved immunotherapy options. Oncologists emphasize that delayed novel options do not diminish the power of current standard-of-care regimens.[2]

Patients currently enrolled in ongoing US-based clinical trials for ivonescimab should consult their trial coordinators. The FDA's rejection of a specific commercial application does not automatically halt all investigational research involving the drug. Clinical trials operate under separate regulatory oversight.[6]

The decision underscores the rigorous safety and efficacy standards protecting American patients. While the desire for rapid innovation is strong, the agency's insistence on proven overall survival ensures that new treatments offer genuine benefits. The regulatory bar remains intentionally high.[4]

Medical teams will continue to rely on established biomarker testing to guide treatment decisions. By analyzing a tumor's specific genetic mutations and PD-L1 expression levels, oncologists can match patients with the most effective available therapies. Precision medicine remains the standard approach.[3]

The rejection of ivonescimab represents a delay in one specific therapeutic avenue, not a failure of the broader immunotherapy revolution. The pipeline for lung cancer treatments remains robust. Dozens of novel compounds are currently advancing through rigorous clinical testing across the globe.[1]

The rejection of ivonescimab represents a delay in one specific therapeutic avenue, not a failure of the broader immunotherapy revolution.

Patients should focus on the therapies available today while researchers refine the treatments of tomorrow. The FDA's decision ensures that when the next generation of lung cancer drugs finally reaches the market, the survival benefits will be proven, measurable, and applicable to the US population.[4][5]

Key points

  1. The FDA rejected the biologics license application for ivonescimab in a specific first-line lung cancer setting.
  2. The underlying clinical trial missed a key overall survival goal, prompting the regulatory block.
  3. The decision derails the immediate US arrival of the highly anticipated PD-1xVEGF bispecific antibody class.
  4. Current FDA-approved immunotherapies remain highly effective and available for lung cancer patients.

What we don’t know

  • Whether the FDA will require an entirely new multi-regional phase 3 clinical trial to prove overall survival.
  • How this regulatory rejection will impact the development timelines of competing PD-1xVEGF bispecific antibodies.
  • The specific statistical margin by which the ivonescimab trial missed its overall survival endpoint.

How we got here

  1. 2024

    Akeso and Summit Therapeutics partner to develop and commercialize ivonescimab in global markets.

  2. Mid-2026

    Ivonescimab demonstrates a 34 percent progression-free survival advantage over pembrolizumab in a China-based clinical trial.

  3. Nov 2026

    The FDA issues a complete response letter rejecting the drug's application for first-line lung cancer treatment in the US.

Regulatory Standard Advocates 60%Biotech Innovators 40%
Regulatory Standard Advocates
Emphasize strict overall survival metrics and diverse trial populations before approving new oncology drugs.
Biotech Innovators
Focus on rapid deployment of novel mechanisms like bispecific antibodies based on strong early progression data.

Perspectives this story doesn't cover

  • Patients currently enrolled in ivonescimab clinical trials
  • Oncologists seeking immediate access to bispecific antibodies

Sources

Source coverage

6 outlets

2 viewpoints surfaced

Regulatory Standard Advocates 60%Biotech Innovators 40%
  1. [1]Fierce PharmaBiotech Innovators

    FDA rejects Summit's ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

    Read on Fierce Pharma →
  2. [2]Endpoints NewsRegulatory Standard Advocates

    FDA rejects Summit, Akeso's ivonescimab in narrow lung cancer setting

    Read on Endpoints News →
  3. [3]BioSpaceBiotech Innovators

    Summit's PD-1xVEGF rejected by FDA in lung cancer

    Read on BioSpace →
  4. [4]ReutersRegulatory Standard Advocates

    US FDA declines to approve Summit lung cancer drug after trial misses key survival goal

    Read on Reuters →
  5. [5]NDTV ProfitRegulatory Standard Advocates

    US FDA Rejects Summit's China-Originated Lung Cancer Drug

    Read on NDTV Profit →
  6. [6]Summit TherapeuticsBiotech Innovators

    Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application

    Read on Summit Therapeutics →
Listen

Comments

Stay informed

Every angle. Every day.

Get Health stories with full source coverage and perspective breakdowns, free every day.